BerGenBio’s selective first-in-class Axl inhibitor, BGB324, Featured in a Poster Presentation at ASCO Annual Meeting 2017
Bergen, Norway, June 6 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications, reported encouraging clinical and in vitro data with its lead, first-in-class Axl inhibitor, BGB324 in patients with high-risk Myeloid Dysplastic Syndrome (MDS) in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 in Chicago, IL.The clinical data presented at ASCO showed that BGB324 could be a promising novel treatment for patients with MDS. One